Recap: Discussing Treatment Updates in CRC With a Patient Advocate
December 26th 2022Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.
Recap: Selinexor, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma
December 20th 2022Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.
Recap: A Review of Selinexor Combination Therapies in Relapsed/Refractory Multiple Myeloma
November 15th 2022In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.